Apolipoprotein E Polymorphism in 385 Patients on Renal Replacement Therapy in Sweden

Roussos, Louis; Ekström, Ulf; Ehle, Peter Nilsson; Öqvist, Björn; Florén, Claes‐Henrik

doi:10.1080/00365590410033443

Cited by 10 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a study by Roussos et al (2004) also suggested the involvement of APOE in renal disease but in their study the implicated allele was APOE3E4 genotype in a subgroup of ESRD patients with NIDDM; however, they did not observe a higher percentage of APOE2 in their cases, compared to controls. Other studies failed to detect any significant differences in APOE genotypes between patients with kidney disease and controls (Feussner et al 1992, Guz et al 2000, Arikan et al 2007).…”

Section: Resultsmentioning

confidence: 90%

Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls

Hubacek

Bloudíčková

Kubínová³

et al. 2009

Biochem Genet

View full text Add to dashboard Cite

The possible association between the end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some, but not all studies. We have analysed the APOE genotypes in 995 haemodialysed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequencies of APOE alleles between the cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (p=0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13-1.67). The strength of the association increased with the time spent on haemodialysis: the odds ratios of all-cause ESRD in patients dialysed for 8 or more years, 1-8 years and less than one year (non-survivors) were 1.27 (0.94-1.71), 1.41 (1.09-1.81) and 1.94 (0.88-4.18), respectively. This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.

show abstract

Section: Resultsmentioning

confidence: 90%

Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls

Hubacek

Bloudíčková

Kubínová³

et al. 2009

Biochem Genet

View full text Add to dashboard Cite

show abstract

“…A total of 16 clinical studies [14,15,18-31] on ESRD and apoE variants published from 1992 and 2008 were identiﬁed, among which seven studies were form Asia [19,22-24,27,29,31], eight from Europe [14,15,20,21,25,26,28,30], and one from North America [18]. The literature review process was shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…In Hubacek et al’s study [13], patients in hemodialysis had higher frequency of ε2 than the control group (15.9% vs. 12.2%). However, Roussos et al [14] found patients with ESRD had no difference of ε2, ε3 and ε4 distribution compared with the control group. Feussner et al also failed to find the association between ε2 and ESRD [15].…”

Section: Introductionmentioning

confidence: 99%

Apolipoprotein E Gene Variants on the Risk of End Stage Renal Disease

et al. 2013

View full text Add to dashboard Cite

ObjectiveEnd-stage renal disease (ESRD) is a severe health concern over the world. Associations between apolipoprotein E (apoE) gene polymorphisms and the risk of ESRD remained inconclusive. This study aimed to investigate the association between apoE gene polymorphisms and ESRD susceptibility.MethodsDatabases including PubMed, Embase, Web of Science and the Cochrane Library were searched to find relevant studies. Meta-analysis method was used synthesize the eligible studies. ResultsSixteen pertinent case-control studies which included 3510 cases and 13924 controls were analyzed. A signiﬁcant association was found between ε2 allele and the ESRD risk (odds ratio (OR) = 1.30, 95% conﬁdence interval (CI) 1.15–1.46, P < 0.0001; I 2 = 18%, P for heterogeneity = 0.24). The ε2ε3, ε2ε4, ε3ε3, ε3ε4, ε4ε4, ε3 and ε4 were not associated with the susceptibility of ESRD. In the subgroup analysis by ethnicity, there was a statistically significant association between ε2ε3 or ε2 allele and ESRD risk in East Asians (OR = 1.66, 95% CI 1.31–2.10, P < 0.0001; OR = 1.62, 95% CI 1.31–2.01, P < 0.0001, respectively), but not in Caucasians. E2 carriers had higher plasma apoE (mean difference = 16.24 mg/L, 95% CI 7.76-24.73, P = 0.0002) than the (ε3 + ε4) carriers in patients with ESRD. The publication bias was not significant.ConclusionThe ε2 allele of apoE gene might increase the risk of ESRD. E2 carriers expressed higher level of plasma apoE in patients with ESRD. More well-designed studies are needed to conﬁrm these associations in the future.

show abstract

“…This may be due in part to the small sample size used in all but one study (70). Several studies (72)(73)(74) concluded that the ApoE4 isoform is associated with protection from type 2 DN in both white and Japanese individuals. Hsu et al (70) corroborated this finding, demonstrating that the frequency of the 4 allele is decreased in type 2 diabetes and chronic kidney disease and revealing association between the 2 allele and chronic kidney disease, a result that is consistent with several older studies of type 1 DN in white individuals (75,76) and one of type 2 DN in Japanese individuals (77).…”

Section: Additional Candidate Genes Of Interestmentioning

confidence: 88%

Genetic Factors in Diabetic Nephropathy

Freedman

Bostrom

Daeihagh

et al. 2007

Clinical Journal of the American Society of Nephrology

174

125

View full text Add to dashboard Cite

Several genes that predispose to type 2 diabetes have recently been identified. In addition to the recognized and powerful effects of environmental factors, there is abundant evidence in support of genetic susceptibility to the microvascular complication of nephropathy in individuals with both type 1 and type 2 diabetes. Familial aggregation of phenotypes such as end-stage renal disease, albuminuria, and chronic kidney disease have routinely been reported in populations throughout the world, and heritability estimates for albuminuria and glomerular filtration rate demonstrate strong contributions of inherited factors. Recent genome-wide linkage scans have identified several chromosomal regions that likely contain diabetic nephropathy susceptibility genes, and association analyses have evaluated positional candidate genes under these linkage peaks. These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to diabetic nephropathy. Additional genes that seem to be of importance in renal phenotypes include manganese superoxide dismutase and angiotensin 1-converting enzyme, with nitric oxide synthase implicated in albuminuria. This article reviews the inherited aspects of diabetic kidney disease with particular emphasis on recently implicated genes and pathways. It seems likely that the risk for diabetes-associated kidney disease is magnified by inheriting risk alleles at several susceptibility loci, in the presence of hyperglycemia.Clin J Am Soc Nephrol 2: 1306 -1316, 2007. doi: 10.2215/CJN.02560607 I t was previously thought that individuals who had diabetes and developed progressive diabetic nephropathy (DN) and/or ESRD were simply exposed to long durations of diabetes with relatively poor glycemic control. In other words, all individuals with diabetes were assumed to be at essentially equivalent risk for developing nephropathy, allowing for differences in their ambient serum glucose concentration. In support of the concept that exposure to a hyperglycemic environment led to DN (often with coexisting obesity, metabolic syndrome, hypertension, and hyperlipidemia), clinical trials have conclusively demonstrated that improving glycemic control delays and, in some cases, may prevent the subsequent development of albuminuria, DN, and macrovascular complications such as coronary artery disease (1,2). The concept that select individuals with diabetes were at differential risk for developing nephropathy on the basis of familial aggregation of kidney disease was initially reported in 1989 but has only recently gained broad acceptance among nephrologists and diabetologists (3). Familial Aggregation of DNThe notion that genetic factors contribute to any complex disease rests on the demonstration of familial aggregation. Familial clustering of nephropathy could result from shared genes, environmental exposures, or their combination.After repeated demonstra...

show abstract

Apolipoprotein E Polymorphism in 385 Patients on Renal Replacement Therapy in Sweden

Cited by 10 publications

References 16 publications

Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls

Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls

Apolipoprotein E Gene Variants on the Risk of End Stage Renal Disease

Genetic Factors in Diabetic Nephropathy

Contact Info

Product

Resources

About